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Contemporary Patterns and Predictors’ [1]. Drs Kang, Li
and Chen note that our findings related to the association
between PICC gauge, cancer and deep vein thrombosis
(DVT) are in accord with the prior literature [2]. They,
however, raise several interesting questions related to
these and other findings in our paper. We address their
concerns individually below.
First, Kang and colleagues suggest that cancer type
and burden may influence the risk of DVT. We agree that
this is often the case. In our study, 35% of the 301
patients with malignancies had advanced or metastatic
disease at the time they were diagnosed with thrombosis.
Considering this population separately using both logistic
and Cox proportional hazards regression models, we did
not find statistically significant differences in the risk of
PICC-related thrombosis in patients with advanced cancer
compared to patients without metastases (odds ratio
[OR] = 2.06, 95% confidence interval [CI] = 0.94–4.43 vs.
OR = 1.81, 95%CI = 0.74–4.45) (Table 1). While this
finding may be limited by statistical power, another plau-
sible explanation is the fact that tumor biology or disease
extent are but one of many characteristics that influence
the risk of thrombosis in patients with cancer [3]. For
example, historical elements such as prior venous throm-
boembolism (VTE) and clinical aspects such as reduced
mobility are also important in determining the risk of
thrombosis in patients with and without cancer [4]. Fur-
thermore, factors such as concurrent infections (com-
monly associated with immune-suppressive therapies)
have been noted to increase the risk of thrombosis in
patients with malignancy and PICCs specifically [5,6]. For
these reasons, we have focused our analytical approach in
PICC DVT on the presence of cancer and related risk
factors, rather than type or stage of malignancy itself.
Second, the authors question whether the use of ICD-9
coding is a reliable method with which to measure VTE
events given the potential overlap between other throm-
botic events in this schema. As we worked with data
from a national Veterans Affairs database, we were able
to adequately parse superficial thromboses, upper and
lower-extremity DVT from one another using a combina-
tion of both ICD-9 and procedure-specific codes within
this data set. This approach increases the reliability of
our findings and averts the typical limitations associated
with ICD-9 data.
Third, the association between the presence of PICC,
upper-extremity DVT and lower-extremity DVT is inter-
esting and worthy of further discussion. As mentioned in
our manuscript, we are in the process of analyzing data
(now from over 72 000 patients) within which we continue
to observe a strong, independent association between
PICC placement and both upper and lower-extremity
DVT. Early analysis of over 50 000 patients has been
published in abstract form and shows that this relation-
ship persists even after adjustment for a number of
important confounders, including patient-, provider- and
device-related characteristics [7]. Notably, this analysis is
also not limited by ICD-9 codes as these data come from
a multi-hospital consortium with direct abstraction of
patient-level information. Therefore, while we concur that
the epidemiology of upper-extremity DVT and that of
lower-extremity DVT have historically been considered
separate entities, we wonder whether this is the right par-
adigm when it comes to PICCs? For example, we hypoth-
esize that PICC-DVT begins as a local process triggered
by the presence of a catheter within a vein that often pro-
gresses to systemic activation of coagulation with distal
manifestations. Further, because many patients who
receive PICCs also harbor underlying risk factors for
lower-extremity DVT (e.g. cancer and immobilization), it
is not inconceivable that PICC placement serves as a trig-
ger for both local and distal thromboses, including embo-
lization of clots to the lung and development of lower
extremity DVT. In this sense, the development of lower
extremity thrombosis in patients with PICCs may simply
‘unmask’ those with an inherent propensity to develop-
thrombosis. Supportively, our analyses of over 72 000
patients suggests that symptomatic PICC DVT remains
Table 1 Predictors of PICC-thrombosis with additional covariates
Variable
Logistic regression Cox proportional hazards
Odds ratio
Confidence
interval P-value Hazard ratio
Confidence
interval P-value
Cancer
Advanced/metastatic 2.055 0.980 4.306 0.06 2.030 0.971 4.245 0.06
Non-metastatic 1.758 0.732 4.222 0.21 1.701 0.718 4.028 0.23
None 1.000 Ref Ref 1.000 Ref Ref
Prior surgery (>1 h) 0.873 0.412 1.848 0.72 0.955 0.461 1.976 0.90
Prior VTE 1.400 0.307 6.334 0.67 0.992 0.207 4.761 0.99
French (gauge)
4 1.000 Ref Ref 1.000 Ref Ref
5 1.867 0.858 4.062 0.12 2.182 1.005 4.735 0.05
6 2.348 0.823 6.698 0.11 3.318 1.187 9.275 0.02
COPD 1.378 0.691 2.746 0.36 1.498 0.747 3.002 0.26
Diabetes 0.962 0.495 1.872 0.91 0.962 0.497 1.861 0.91
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associated with lower-extremity DVT following adjust-
ment for a number of risk factors. We anticipate submit-
ting this work for peer-review soon and look forward to
continued discussion as to whether these disease states
should be considered separate or a spectrum of severity in
the specific case of PICCs.
Fourth, with respect to the interaction between PICC
lumens and device diameter, we agree that these values
are often correlated. However, most physicians do not
consider PICC diameter when requesting a PICC; rather,
many remain clinically attuned to number of lumens.
While we acknowledge that the growing availability of
smaller diameter multi-lumen PICCs is helpful, such
devices are far from ubiquitous. Thus, use of alternate
devices or clinical decision-aids that ensure the right
device is ordered are highly appropriate and necessary
steps. Notably, the assumption that a smaller PICC diam-
eter will translate into lower VTE rates ignores the signifi-
cance of other important characteristics (such as PICC
tip location, dwell time and care processes). Thus, a com-
posite approach that incorporates several patient-, pro-
vider- and device-related characteristics is needed to
prevent this adverse outcome.
Fifth, we recognize the potential for confounding
related to gender bias and mention these limitations
within our manuscript. With respect to the incremental
risk burden associated with diabetes and/or COPD, we
are unsure if these clinical markers are more likely to
cause thromboses in patients with cancer. While we are
aware of the existence of studies that have suggested this
association in non-cancer populations, repeat analyses
with these variables revealed no differences in the
observed estimates in both our logistic and Cox propor-
tional hazards models (Table 1). Future studies that
examine the incremental risk of these clinical factors are
necessary to understand whether they are clinically mean-
ingful in the context of the underlying hypercoaguable
drive associated with malignancy and/or the presence of
PICCs.
Finally, Drs Kang and colleagues state that our concep-
tual model may not be suitable for cancer or those with
asymptomatic thrombosis. We respond by quoting the
famous statistician, George E.P. Box, who once said,
‘essentially all models are wrong, but some are useful’. In
this spirit, we created a conceptual model that began first
by looking within the evidence base. Our aim was to create
a useful framework, one that researchers, clinicians and
policy-makers alike could apply to any PICC-complication,
not just DVT. Thus, like any good conceptual schema, our
model had to meet several important characteristics
(Table 2) [8,9]. Through our work to date, we believe our
model for PICC-DVT meets many of these standards and
are gratified that is has been applied successfully by others
and us in the field [10,11]. However, future studies that
adapt this conceptual framework to specific settings (e.g.
asymptomatic thrombosis) or more specific patient cohorts
(e.g. patients with cancer) would be welcomed. We encour-
age Dr Kang and colleagues to consider adapting and test-
ing our framework for this purpose.
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